Heart Defects, Congenital
Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life.
Subtype terms (34)
More specific conditions that are subtypes of Heart Defects, Congenital in the MeSH hierarchy.
- 22q11 Deletion Syndrome
7 drugs (6 approved, 1 experimental)
- Alagille Syndrome
6 drugs approved
- Aortic Coarctation
9 drugs (8 approved, 1 experimental)
- Aortico-Ventricular Tunnel
- Arrhythmogenic Right Ventricular Dysplasia
5 drugs (2 approved, 3 experimental)
- Barth Syndrome
2 drugs approved
- Bicuspid Aortic Valve Disease
3 drugs (2 approved, 1 experimental)
- Coronary Vessel Anomalies
1 drug experimental
- Cor Triatriatum
- Crisscross Heart
- Dextrocardia
- Ductus Arteriosus, Patent
13 drugs (10 approved, 3 experimental)
- Ebstein Anomaly
3 drugs (2 approved, 1 experimental)
- Ectopia Cordis
- Eisenmenger Complex
7 drugs (6 approved, 1 experimental)
- Heart Septal Defects
- Heterotaxy Syndrome
- Hypoplastic Left Heart Syndrome
18 drugs (8 approved, 10 experimental)
- Isolated Noncompaction of the Ventricular Myocardium
- LEOPARD Syndrome
- Levocardia
- Long QT Syndrome
15 drugs (11 approved, 4 experimental)
- Marfan Syndrome
9 drugs approved
- Noonan Syndrome
7 drugs approved
- Quadricuspid Aortic Valve
- Tetralogy of Fallot
13 drugs (11 approved, 2 experimental)
- Transposition of Great Vessels
5 drugs (4 approved, 1 experimental)
- Tricuspid Atresia
5 drugs approved
- Trilogy of Fallot
- Trisomy 13 Syndrome
- Trisomy 18 Syndrome
- Turner Syndrome
15 drugs (12 approved, 3 experimental)
- Univentricular Heart
3 drugs (1 approved, 2 experimental)
- Wolff-Parkinson-White Syndrome
4 drugs approved
Drugs by status
Approved for this indication (2)
Phase 4 trials (20)
Phase 3 trials (21)
Phase 2 trials (29)
- vitamin d3
- iron
- oxandrolone
- theophylline
- acetylcysteine
- epoetin
- dextran
- progesterone
- adenosine
- iloprost
- tryptophan
- levosimendan
- motavizumab
- human factor ix complex (prothrombin complex concentrate)
- propranolol
- treprostinil
- spironolactone
- autologous platelets
- autologous umbilical cord blood
- l-histidine
- dexmedetomidine
- losartan
- ketoglutarate
- sodium bicarbonate
- blood plasma
- sodium chloride
- milrinone
- phenoxybenzamine hydrochloride
- crd-4730
Phase 1 trials (9)
Other trials (27)
- simvastatin
- methylprednisolone
- bifidobacterium animalis
- calcium citrate
- folic acid
- isoflurane
- famotidine
- potassium
- insulin human
- ketorolac
- inulin
- human milk
- cow milk
- acetaminophen
- potassium chloride
- red blood cells
- immune globulin (human)
- bupivacaine
- xuebijing
- ramipril
- irradiated donor lymphocyte
- midazolam
- oxygen
- morphine
- perindopril
- b multivitamins
- lactobacillus rhamnosus
Organizations
Organization Involved with Phase 4 Indications (13)
- Techpool Bio-Pharma Co., Ltd.
- University of London
- Cukurova University
- Emory University
- Guangzhou Medical University
- Nanjing Medical University
- Fudan University
- University of California, Los Angeles
- University of Indonesia
- Jiao Tong University
- University of Sao Paulo
- Harapan Kita Hospital, Jakarta, Indonesia
- People's Liberation Army of China
Organization Involved with Phase 3 Indications (32)
- Asklepion
- Bristol-Myers Squibb
- Sanofi
- Ethicare GmbH
- Mallinckrodt
- Swiss National Science Foundation
- ZonMw: The Netherlands Organisation for Health Research and Development
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Pennsylvania
- Harvard University
- Duke University
- University of Washington
- New England Research Institutes
- Radboud University
- Thomas Jefferson University
- University of Groningen
- University of Toronto
- Utrecht University
- University of Bern
- University of Cincinnati
- University of Utah
- Vanderbilt University
- Medical University of South Carolina
- University of Vienna
- Leiden University
- University of Amsterdam
- Free University of Amsterdam
- Moscow State University
- Novosibirsk Research Institute of Circulation Pathology
- Erasmus University Rotterdam
- +2 more
Organization Involved with Phase 2 Indications (18)
- Actelion
- MedImmune
- Dong-A Pharmaceutical
- Aarhus University
- American Heart Association
- Children's University Hospital, Ireland
- McGill University
- Oregon Health and Science University
- Osaka University
- University of Ottawa
- University of California, San Diego
- University of Copenhagen
- University of Gothenburg
- Washington University in St. Louis
- The Interuniversity Cardiology Institute of the Netherlands
- BioPhausia
- University of Helsinki
- National University of Ireland
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (12)
- United Therapeutics
- Pfizer
- The Gerber Foundation
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- National Center for Research Resources (NCRR)
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Dr. Sami Ulus Children's Hospital
- Medical College of Wisconsin
- Stanford University
- University Hospital of North Norway
- Capital Medical University
- University of Wisconsin